Immunotherapy for Infectious Diseases

Passive Immunotherapy for HIV Infection 219
114. Andrus L, Prince AM, Bernal I, et al. Passive immunization with a human immunodeficiency
virus type 1-neutralizing monoclonal antibody in Hu-PBL-SCID mice; isolation of
a neutralization escape variant. J Infect Dis 1998; 177:889–897.
115. Koup RA, Safrit JT, Weir R, Gauduin M-C. Defining antibody protection against HIV-1
transmission in Hu-PBL-SCID mice. Semin Immunol 1996; 8:263–268.
116. Andrus L, McCarthy M, Cobb KE, et al. Passive immunization against HIV-1 infection.
In: Girard M, Valette L (eds). Retroviruses of Human AIDS and Related Animal Diseases.
Paris: Foundation Merieux, 1993, pp. 251–257.
117. Parren PW, Ditzel HJ, Gulizia RJ, et al. Protection against HIV-1 infection in hu-PBL-
SCID mice by passive administration with a neutralizing monoclonal antibody against the
gp120-binding site. AIDS 1995; 9:F1–F6.
118. Gauduin M-C, Parren PWHI, Weir R, Barbas CF, Burton DR, Koup RA. Passive immunization
with a human monoclonal antibody protects hu-PBL-SCID mice against challenge
by primary isolates of HIV-1. Nat Med 1997; 3:1389–1393.
119. Okamoto Y, Eda Y, Ogura A, et al. In SCID-hu mice, passive transfer of a humanized antibody
prevents infection and atrophic change of medulla in human thymic implant due to
intravenous inoculation of primary HIV-1 isolate. J Immunol 1998; 160:69–76.
120. Schutten M, Tenner-Racz K, Racz P, van Bekkum DW, Osterhaus AD. Human antibodies
that neutralize primary human immunodeficiency virus type 1 in vitro do not provide protection
in an in vivo model. J Gen Virol 1996; 77:1667–1675.
121. Moore JP, Nara PL. The role of the V3 loop of gp120 in HIV infection. AIDS 1994;
5:S21–S33.
122. Trkola A, Dragic T, Arthos J, et al. CD4-dependent, antibody-sensitive interactions
between HIV-1 and its co-receptor CCR-5. Nature 1996; 384:184–187.
123. Gauduin M-C, Weir R, Fung MSC, Koup RA. Involvement of the complement system in
antibody-mediated post-exposure protection against human immunodeficiency virus type
1. AIDS Res Hum Retroviruses 1998; 14:205–211.
124. Jackson GG, Perkins JT, Rubenis M, et al. Passive immunoneutralization of human
immunodeficiency virus in patients with advanced AIDS. Lancet 1988; 2:647–654.
125. Karpas A, Hill F, Youle M, et al. Effects of passive immunization in patients with the
acquired immunodeficiency syndrome-related complex and acquired immunodeficiency
syndrome. Proc Natl Acad Sci USA 1988; 85:9234–9237.
126. Busch MP, Henrard DR, Hewlett IK, et al. Poor sensitivity, specificity, and reproducibility
of detection of HIV-1 DNA in serum by polymerase chain reaction. The Transfusion
Safety Study Group. J Acquir Immune Defic Syndr 1992; 5:872–877.
127. Jacobson JM, Colman N, Ostrow NA, et al. Passive immunotherapy in the treatment of
advanced human immunodeficiency virus infection. J Infect Dis 1993; 168:298–305.
128. Vittecoq D, Mattlinger B, Barre-Sinoussi F, et al. Passive immunotherapy in AIDS: a randomized
trial of serial human immunodeficiency virus-positive transfusions of plasma rich
in p24 antibodies versus transfusions of seronegative plasma. J Infect Dis 1992; 165:364–368.
129. Levy J, Youvan T, Lee ML. Passive hyperimmune plasma therapy in the treatment of
acquired immunodeficiency syndrome: results of a 12 month multicenter double-blind
controlled trial. Blood 1994; 84:2130–2135.
130. Vittecoq D, Chevret S, Morand-Joubert L, et al. Passive immunotherapy in AIDS: a
double-blind randomized study based on transfusions rich in anti-human immundeficiency
virus 1 antibodies vs transfusions of seronegative plasma. Proc Natl Acad Sci USA 1995;
92:1195–1199.
131. Morand-Joubert L, Vittecoq D, Roudot-Thoraval F, et al. Virological and immunological
data of AIDS patients treated by passive immunotherapy (transfusions of plasma rich in
HIV-1 antibodies). Vox Sang 1997; 73:149–154.
132. Osther K, Wiik A, Black F, et al. PASSHIV-1 treatment of patients with HIV-1 infection.
A preliminary report of a phase 1 trial of hyperimmune porcine immunoglobulin to
HIV-1. AIDS 1992; 6:1457–1464.